Sangui Biotech International, Inc. Announces Earnings Results for the Second Quarter and First Half of 2019
February 14, 2019 at 04:24 am EST
Share
Sangui Biotech International, Inc. announced earnings results for the second quarter and first half of 2019, for the first half, the company achieved revenues from royalty income of USD 55,367. In the same period of the previous year the comparable revenue amounted to USD 55,082. Operating loss increased USD 44,510 to USD 153,635 from the prior year.
For the second quarter of 2019, the company operating loss for the second quarter of 2019, on the other hand, increased disproportionately by USD 8,801 compared to the previous year to USD 60,137.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
